Liver MASLD: Head-to-Head Comparisons

4 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.

4articles

3topic areas covered

May 25, 2026latest review

Liver MASLD: Head-to-Head Comparisons library

Showing 4 of 4 clinical reviews.

AccessMay 25, 2026

Rezdiffra (Resmetirom) vs Actos (Pioglitazone): Cost and Access Head-to-Head

A clinical comparison of Rezdiffra (resmetirom) and Actos (pioglitazone) for MASH/MASLD, covering cost, insurance coverage, efficacy data from MAESTRO-NASH and PIVENS, and practical access guidance.

ComparisonsMay 26, 2026

Rezdiffra (Resmetirom) vs Actos (Pioglitazone): Head-to-Head Efficacy for MASH

A clinical comparison of resmetirom and pioglitazone for metabolic dysfunction-associated steatohepatitis (MASH), covering trial data, histological endpoints, side effects, and prescribing considerations.

SafetyMay 26, 2026

Rezdiffra (Resmetirom) vs Actos (Pioglitazone): Side-Effect Profile Head-to-Head

A clinical comparison of the side-effect profiles of resmetirom (Rezdiffra) and pioglitazone (Actos) for MASH/MASLD, including trial data from MAESTRO-NASH and PIVENS, tolerability, weight effects, and safety monitoring.

ComparisonsMay 25, 2026

Rezdiffra (Resmetirom) vs Actos (Pioglitazone): Switching Between Them

A clinical comparison of resmetirom and pioglitazone for MASH, including mechanisms, trial data, side-effect profiles, and how to switch safely between the two drugs.